drugset
drugset / Trial / NCT01968486

Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia

NCT01968486 ↗

Phase 1 Completed 60 enrolled University of Campania Luigi Vanvitelli
RandomizedParallel-groupOpen-labelTreatment

Summary

To demonstrate the efficacy of ranibizumab in combination with reduced-fluence verteporfin photodynamic therapy (RF-PDT) in patients with subfoveal choroidal neovascularization secondary to pathologic myopia (PM).

Timeline

Start
2012-06
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal
Subject Verteporfin Other / unclassified 6 mg/m2 —

Indications

degenerative myopia